NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

Compare
797.45 +21.07 (+2.71%)
At close: 7 November at 4:00 pm GMT-5
801.60 +4.15 (+0.52%)
Pre-market: 5:35 am GMT-5
Advanced chart
Loading Chart for LLY
DELL
  • Previous close 776.38
  • Open 784.65
  • Bid 799.00 x 800
  • Ask 808.00 x 800
  • Day's range 778.19 - 802.51
  • 52-week range 561.65 - 972.53
  • Volume 3,993,164
  • Avg. Volume 3,136,220
  • Market cap (intra-day) 757.032B
  • Beta (5Y monthly) 0.43
  • PE ratio (TTM) 86.21
  • EPS (TTM) 9.25
  • Earnings date 4 Feb 2025 - 10 Feb 2025
  • Forward dividend & yield 5.20 (0.65%)
  • Ex-dividend date 15 Nov 2024
  • 1y target est 1,002.82

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com

43,000

Full-time employees

31 December

Fiscal year ends

Healthcare

Sector

Drug Manufacturers - General

Industry

More about Eli Lilly and Company

Recent news: LLY

View more
View more

Related videos: LLY

Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences.

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter revenue and raised its outlook. The telehealth company swung to a profit, helped by a tax benefit and strong demand for GLP-1 weight-loss drugs. In an interview on Market Domination Overtime, Hims & Hers Health CFO Yemi Okupe speaks with anchors Julie Hyman and Josh Lipton about the quarter. "We saw revenue up 77% year-over-year to north of 4$00 million. Simultaneously, we're also seeing very strong EBITDA margins at north of 13%," Okupe says. "Additionally, at the end of the quarter, we also saw 2 million consumers on the platform, of which 1 million were benefiting from a personalized solution. And so really, the strong results that we're seeing in the third quarter are a reflection of us executing across the strategy that we've held for the past couple of years." Okupe also addresses a possible headwind for the company, that Eli Lilly (LLY)'s and Novo Nordisk (NVO)'s weight-loss drugs are coming off the FDA's (Food and Drug Administration) shortage lists. But Okupe says it's not a concern right now, but acknowledges the shortages will come to an end."In our view, we do still see that the medications are on on shortage. And what we do see on our platform. And this is the benefit of being a consumer oriented platform, is that we hear feedback directly from consumers and what consumers are telling us, you know resoundingly, is that they are struggling to get access to name-brand GLP-1 medications over the last two months," according to Okupe. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. This post was written by Rachel Sherman.
Yahoo Finance Video · 3 days ago
NVO
+2.15%
NONOF
-0.93%

Performance overview: LLY

Trailing total returns as of 07/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD return

LLY
37.47%
S&P 500
25.23%

1-year return

LLY
34.88%
S&P 500
36.81%

3-year return

LLY
210.55%
S&P 500
27.15%

5-year return

LLY
650.58%
S&P 500
94.13%

Compare to: LLY

Compare

Select to analyse similar companies using key performance metrics; select up to four stocks.

LLY
Eli Lilly and Company
797.45
+2.71%
Mkt cap 757.032B
Industry Drug Manufacturers—General
NVO
Novo Nordisk A/S
107.63
+2.15%
Mkt cap 488.919B
Industry Drug Manufacturers—General
PFE
Pfizer Inc.
27.46
+0.37%
Mkt cap 155.616B
Industry Drug Manufacturers—General
MRK
Merck & Co., Inc.
101.17
+0.44%
Mkt cap 255.924B
Industry Drug Manufacturers—General
ABBV
AbbVie Inc.
200.51
-0.34%
Mkt cap 354.329B
Industry Drug Manufacturers—General
BMY
Bristol-Myers Squibb Company
54.71
-1.03%
Mkt cap 110.962B
Industry Drug Manufacturers—General
JNJ
Johnson & Johnson
156.73
-0.73%
Mkt cap 377.346B
Industry Drug Manufacturers—General
AZN
AstraZeneca PLC
64.69
+1.32%
Mkt cap 200.607B
Industry Drug Manufacturers—General
AMGN
Amgen Inc.
321.91
+0.04%
Mkt cap 173.037B
Industry Drug Manufacturers—General
GILD
Gilead Sciences, Inc.
97.90
+6.77%
Mkt cap 121.983B
Industry Drug Manufacturers—General
NOVO-B.CO
Novo Nordisk A/S
742.90
+1.77%
Mkt cap DKK 3.306T
Industry Drug Manufacturers—General

Statistics: LLY

View more

Valuation measures

As of 07/11/2024

  • Market cap

    757.03B

  • Enterprise value

    784.63B

  • Trailing P/E

    85.93

  • Forward P/E

    35.09

  • PEG ratio (5-yr expected)

    0.75

  • Price/sales (ttm)

    17.65

  • Price/book (mrq)

    53.16

  • Enterprise value/revenue

    19.20

  • Enterprise value/EBITDA

    62.70

Financial highlights

Profitability and income statement

  • Profit margin

    20.48%

  • Return on assets (ttm)

    13.95%

  • Return on equity (ttm)

    65.32%

  • Revenue (ttm)

    40.86B

  • Net income avi to common (ttm)

    8.37B

  • Diluted EPS (ttm)

    9.25

Balance sheet and cash flow

  • Total cash (mrq)

    3.52B

  • Total debt/equity (mrq)

    218.08%

  • Levered free cash flow (ttm)

    -1.31B

View more

Research analysis: LLY

View more

Earnings per share

Consensus EPS
 

Revenue vs. Earnings

Revenue 11.44B
Earnings 970.3M
Q4'23
Q1'24
Q2'24
Q3'24
0
2B
4B
6B
8B
10B
 

Analyst recommendations

  • Strong buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analysts' price targets

700.00 Low
1,002.82 Average
797.45 Current
1,250.00 High
 
View more

People also watch

BMY Bristol-Myers Squibb Company
54.71
-1.03%
 
MRK Merck & Co., Inc.
101.17
+0.44%
 
ABT Abbott Laboratories
115.30
-1.28%
 
NVO Novo Nordisk A/S
107.63
+2.15%
 
AMGN Amgen Inc.
321.91
+0.04%
 
JNJ Johnson & Johnson
156.73
-0.73%
 
ABBV AbbVie Inc.
200.51
-0.34%
 
UNH UnitedHealth Group Incorporated
605.45
+1.47%
 
PFE Pfizer Inc.
27.46
+0.37%
 
AVGO Broadcom Inc.
183.81
+2.37%
 
AZN AstraZeneca PLC
64.69
+1.32%
 
GSK GSK plc
36.66
+2.12%
 
MDT Medtronic plc
88.12
-2.21%
 
GILD Gilead Sciences, Inc.
97.90
+6.77%
 
NVS Novartis AG
107.08
+0.25%
 
COST Costco Wholesale Corporation
913.93
+1.63%